Shuichi Ohkubo

Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Activation of DCTN1-RET Fusion Through Coiled-coil Domain as a Potential Target for RET Inhibitors.

Activation of DCTN1-RET Fusion Through Coiled-coil Domain as a Potential Target for RET Inhibitors.

Journal: Anticancer research

Published: February 20, 2025

LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC.

LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC.

Journal: Nature communications

Published: January 02, 2025

The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment.

The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment.

Journal: Cancer immunology research

Published: July 29, 2024

Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor-Insensitive Breast Cancer Cells.

Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor-Insensitive Breast Cancer Cells.

Journal: Cancer science

Published: June 30, 2024

Author Correction: Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy.

Author Correction: Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy.

Journal: Scientific reports

Published: February 27, 2024

Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors.

Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors.

Journal: Future oncology (London, England)

Published: December 05, 2023

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.

Journal: Nature cancer

Published: October 09, 2023

Characterization of cell line with dedifferentiated GIST-like features established from cecal GIST of familial GIST model mice.

Characterization of cell line with dedifferentiated GIST-like features established from cecal GIST of familial GIST model mice.

Journal: Pathology international

Published: December 12, 2022

Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors.

Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors.

Journal: International journal of cancer

Published: November 21, 2022

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.

Journal: Nature cancer

Published: June 10, 2022

Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy.

Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy.

Journal: Scientific reports

Published: April 08, 2022

TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models.

TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models.

Journal: Molecular cancer therapeutics

Published: December 28, 2021

Showing 1-12 of 29

Last Updated: 09/26/2026